ReviewHeart failure reviews2026
Predicting sudden cardiac death in heart failure with reduced ejection fraction.
Review in Heart failure reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systemic Neutralization of Granulocyte-Macrophage Colony-Stimulating Factor Attenuates Stellate Ganglion Neuroinflammation and Cardiac Sympathetic Overactivation in Chronic Heart Failure in Rats.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sudden cardiac death (SCD) accounts for up to half of all mortality in patients with heart failure with reduced ejection fraction, yet contemporary clinical practice continues to rely primarily on left ventricular ejection fraction (LVEF) despite its well-recognized limitations as a predictor of arrhythmic risk. Many patients who experience SCD have only mildly reduced or even preserved LVEF, while a substantial proportion with severely reduced LVEF never develop life-threatening arrhythmias, underscoring the need for more precise risk assessment tools. This review synthesizes current evidence on clinical features, comorbidities, biomarkers, electrocardiographic abnormalities, and advanced imaging markers that independently inform SCD risk, including high-risk indicators such as syncope, chronic kidney disease, ventricular arrhythmias, impaired global longitudinal strain, and myocardial fibrosis on cardiac MRI. We also summarize emerging multiparametric risk models that integrate these variables into clinically usable frameworks, offering more individualized risk estimates than ejection fraction alone. Finally, we outline contemporary prevention strategies that optimize guideline-directed medical therapy and targeted device therapy, while discuss the evolving role of precision-medicine approaches in guiding ICD decision-making. Collectively, these data highlight the importance of moving beyond LVEF-centric algorithms toward more nuanced, multimodal strategies to better identify high-risk patients and reduce the ongoing burden of SCD in heart failure patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.